Followers | 20 |
Posts | 5354 |
Boards Moderated | 0 |
Alias Born | 01/04/2012 |
Sunday, October 23, 2016 8:42:59 AM
The fact ANI paid the required fees without submitting a response to the last office action is indicative of something else being in the works. It also signals to the examiner that they, or another partie, intends to continue prosecuting the patent application. Otherwise, why pay the extension of time fee?
The fact that both the Commercial Scale Production and the CV Risk Reduction patent applications are in a status of Abandonment for Failure to Respond to an Office Action with both having fees to extend time paid up and granted, increases the possibility that the patents have been re-assigned, at least partially, to a third party or that the next submission could point to a partnership, that they are not ready to announce.
If, as I suspect, Abbvie is the partner, the FDA approving Amgen's Amjevita as a biosimilar for Humira on September 23, 2016 and J&J's Guselkumab outperforming Humira for treating psoriasis in clinical trials, may be the driving force to get Libigel or whatever it will be called moving, even while they work to secure patents. In the meantime they do have the patent protection assigned to Antares for testosterone restoration.
Guselkumab
Amjevita
Antares patent
Recent ANIP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 12:03:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 12:02:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:58:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:54:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:45:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:06:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 10:14:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:21:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2024 08:57:32 PM
- ANI Pharmaceuticals Announces the Launch of Kionex® Suspension • GlobeNewswire Inc. • 05/20/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:50:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/16/2024 09:02:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:02:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/16/2024 08:49:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2024 08:59:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2024 11:47:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:11:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 09:25:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 11:09:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 10:55:18 AM
- ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance • GlobeNewswire Inc. • 05/10/2024 10:50:00 AM
- ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences • GlobeNewswire Inc. • 05/01/2024 08:30:00 PM
- ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET • GlobeNewswire Inc. • 04/18/2024 08:05:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM